NDRA· Health Care› Diagnostics & Research

ENDRA Life Sciences Inc.

Stage 2 · Advancing · week 7

As of Oct 22, 2026, ENDRA Life Sciences is in Stage 2, the uptrend phase, now in week 7 (since Sep 8, 2026). It closed at $4.78, 28.7% below its 52-week high and below its 200-day average, which is rising.

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. More about the company

$4.78

+2.14% today

$7.2M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is NDRA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S4 63w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 17w → S1 5w → S2 5w → S3 1w → S4 63w → S1 1w → S4 6w → S1 5w → S2 6w → S3 4w → S2 9w → S3 6w → S4 10w → S1 6w → S2 5w → S3 3w → S2 2w → S3 5w → S2 6w current

Total tracked: 165 weeks across 19 stage runs.

NDRA among Diagnostics & Research33rd of 44 by relative strength

All 44 →

Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CDNACareDx, Inc.	Stage 2 · wk 24	99	+27.3%
2	BDSXBiodesix, Inc.	Stage 2 · wk 18	98	−18.3%
3	ILMNIllumina, Inc.	Stage 2 · wk 24	97	+5.5%
4	GHGuardant Health, Inc.	Stage 2 · wk 21	97	−7.6%
5	NTRANatera, Inc.	Stage 2 · wk 20	96	+2.7%
6	CRLCharles River Laboratories International, Inc.	Stage 2 · wk 16	92	+22.5%
7	RVTYRevvity, Inc.	Stage 2 · wk 18	90	+10.7%
8	PSNLPersonalis, Inc.	Stage 2 · wk 17	90	−3.2%
…33	NDRAENDRA Life Sciences Inc.	Stage 2 · wk 7	38	−26.5%

vs 52W High

-28.7%

$3.26 lo$6.70 hi

28.7% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 7

1w13w26w

Week 7, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-0.4%

200 DMA: $4.80 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.30x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-26.5%

-1.6%

-4.4%

YTD

+11.4%

-22.0%

Scan Membership

Breakout Watch

Latest: 2024-01-22

4 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 7 · Vol 0.30x

2026-10-21S2

Wk 7 · Vol 0.48x

2026-10-20S2

Wk 7 · Vol 0.56x

2026-10-19S2

Wk 6 · Vol 0.26x

2026-10-16S2

Wk 6 · Vol 0.40x

2026-10-15S2

Wk 6 · Vol 0.30x

2026-10-14S2

Wk 6 · Vol 0.41x

2026-10-13S2

Wk 6 · Vol 0.08x

2026-10-12S2

Wk 5 · Vol 0.43x

2026-10-09S2

Wk 5 · Vol 0.63x

2026-10-08S2

Wk 5 · Vol 0.35x

2026-10-07S2

Wk 5 · Vol 0.20x

Moving averages & range

50 DMA

$5.40

200 DMA

$4.80

52W High

$6.70

52W Low

$3.26

5D Low

$4.47

Resistance levels (recent highs)

20d High

$6.31

60d High

$6.50

120d High

$6.50

250d High

$6.70

Next resistance

+32.0%

to 20d High

ROE

-152.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.1

ENDRA Life Sciences: quick answers

What stage is ENDRA Life Sciences in?

As of Oct 22, 2026, ENDRA Life Sciences (NDRA) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 8, 2026 and is in week 7. What the four stages mean

Is ENDRA Life Sciences in an uptrend?

Yes. ENDRA Life Sciences is in a Stage 2 uptrend. It trades 0.4% below its 200-day average, which is rising.

How far is ENDRA Life Sciences from its 52-week high?

ENDRA Life Sciences closed at $4.78 on Oct 22, 2026, 28.7% below its 52-week high of $6.70. Its 52-week low is $3.26.

How has ENDRA Life Sciences performed over the past year?

As of Oct 22, 2026, ENDRA Life Sciences is down 22.0% over the past year and up 11.4% so far in 2026.

Which sector and industry is ENDRA Life Sciences in?

ENDRA Life Sciences is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.